Zomedica CorpChange company Symbol lookupSelect an option...ZOM Zomedica CorpDPW DPW Holdings IncIWN iShares Russell 2000 Value ETFXNXCX Nuveen California Select Tax-Free Income PortfolioAMGN Amgen IncAMSC American Superconductor CorpCVBF CVB Financial CorpPHG Koninklijke Philips NVIVR Invesco Mortgage Capital IncCORE Core-Mark Holding Company IncGo
Change company Symbol lookup
Select an option...
ZOM Zomedica Corp
DPW DPW Holdings Inc
IWN iShares Russell 2000 Value ETF
XNXCX Nuveen California Select Tax-Free Income Portfolio
AMGN Amgen Inc
AMSC American Superconductor Corp
CVBF CVB Financial Corp
PHG Koninklijke Philips NV
IVR Invesco Mortgage Capital Inc
CORE Core-Mark Holding Company Inc
Health Care : Pharmaceuticals | Small Cap Growth
Company profileZomedica Corp., formerly Zomedica Pharmaceuticals Corp., is a development stage veterinary diagnostic and pharmaceutical company. The Company is engaged in developing products for companion animals, such as canine, feline, and equine by focusing on needs of clinical veterinarians. It is focused on developing three diagnostic platforms, a Bulk Acoustic Wave sensor-based veterinary point-of-care diagnostic platform for performing immunodiagnostic testing, a Raman spectroscopy-based point-of-care diagnostic platform for the detection of pathogens, and liquid biopsy assays for the detection of cancer, along with related consumables. The Company’s TRUFORMA product candidate is an investigational device being developed as a point-of-care biosensor platform. ZM-020 is its diagnostic platform being developed to screen for a range of pathogens in companion animal feces, urine, respiratory, and dermatological samples. It is developing ZM-017 as a canine cancer liquid biopsy platform.
Premarket |
|
|
| ||
Market Hours |
|
|
|
|
|
| Latest Earnings (Year ending 12/2019) | Upcoming Announcement (Year ending 12/2020) | ||||||
|---|---|---|---|---|---|---|---|
Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. | -$0.19 | Estimate remained unchanged in year leading up to announcement | -- | Consensus estimate | -$0.03 | Consensus estimate is higher than previous year actual | 84.21% |
| Consensus estimate | -$0.17 | Previous year actual | -$0.19 | ||||
Annual Consensus Estimate Trends over Time
ZOM's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2021. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.